NeRRe Raises £20M to Develop Orvepitant for IPF Chronic Cough
NeRRe Therapeutics has raised £20 million (nearly $28 million) to develop orvepitant as a treatment for the chronic cough that can impact quality of life for people with idiopathic pulmonary fibrosis (IPF). Orvepitant’s efficacy has been demonstrated in patients with refractory or unexplained chronic cough associated with reflex…